SCHEMBL8687687

SCHEMBL8687687

Cc1ncsc1CC/C(=C1\SC(=O)NC1=O)c1cccc2[nH]ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 4/20 0.42
▸ CNR1 P21554 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ KMT2A Q03164 3/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ MAPT P10636 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8686386 0.79 HPGD (0.38) HPGDKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL8687636 0.77 ADRB3 (0.36) CNR2KMT2AMEN1KDM4EMAPK1
SCHEMBL8685055 0.76 MAPK14 (0.43) HPGDHDAC1HDAC2HDAC3HDAC4
SCHEMBL8690619 0.73 IGF1R (0.40) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL8686336 0.73 TUBB4A (0.34) HTR1AHDAC1HDAC2HDAC3HDAC4
SCHEMBL8685374 0.73 PIM1 (0.36) HDAC1HDAC2DHPSTUBB4ATUBB
SCHEMBL8686689 0.73 HPGDS (0.41) HPGDCNR2KMT2AALDH1A1CYP1A2
SCHEMBL8686452 0.72 MEN1 (0.37) HPGDKMT2AMEN1ALDH1A1LMNA
SCHEMBL8687931 0.71 PTGER3 (0.35) LMNAHDAC1HDAC2HDAC3HDAC4
SCHEMBL8686631 0.71 MAPK14 (0.37) CNR1KMT2AMEN1MAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5811439-A ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS SENGA PHARMACEUTICAL LABORATORY INC. (JP) 1998-09-22 — — US disclosed
Send feedback